3 terminated, 2 completed, 1 recruiting, 1 unknown. 7 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Terminated 3, Completed 2, Recruiting 1, Unknown 1 |
| Phase 2 | 1 | Terminated 1 |
Follow OncoTherapy Science, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma OTSA101-DTPA-111In, OTSA101-DTPA-90Y - Relapsed or Refractory Synovial Sarcoma | Phase 1 | Terminated | OncoTherapy Science, Inc. | 12 | 2020-01-10 | 2024-02-02 |
| Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study. OTSGC-A24, Nivolumab, Ipilimumab - Gastric Cancer | Phase 1 | Unknown | National University Hospital, Singapore | 40 | 2019-02-21 | 2019-04-08 |
| Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer OTS167PO - Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer | Phase 1 | Recruiting | OncoTherapy Science, Inc. | 70 | 2017-05-29 | 2026-02-25 |
| Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia OTS167IV - AML, Advanced MDS | Phase 1 / Phase 2 | Terminated | OncoTherapy Science, Inc. | 32 | 2016-04-01 | 2021-11-24 |
| Study to Evaluate Systemic Bioavailability of Oral OTS167 in Healthy Adult Subjects OTS167IV, Cherry syrup - Healthy | Phase 1 | Completed | OncoTherapy Science, Inc. | 11 | 2016-01-01 | 2017-06-01 |
| Phase 1 Study of OTS167 in Patients With Solid Tumors OTS167IV - Solid Tumors, Metastatic Tumors | Phase 1 | Completed | OncoTherapy Science, Inc. | 32 | 2013-08-23 | 2017-06-01 |
| First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 OTSA101-DTPA-90Y level 1, OTSA101-DTPA-90Y level 2, OTSA101-DTPA-90Y level 3 - Sarcoma, Synovial | Phase 1 | Terminated | Centre Leon Berard | 20 | 2011-12-01 | 2017-05-17 |
Recurrence (3) · Sarcoma, Synovial (2) · Breast Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Ipilimumab (1) · Nivolumab (1)
United States (3) · Australia (1) · France (1) · Japan (1) · Singapore (1)
Olatoyosi Odenike, MBBS (1) · Sepehr Shakib (1) · Wei Peng Yong (1)
2018 (1)